Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Protocol # 21-132

Status

Active, not recruiting

Description

This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.

Condition

  • B-Cell Malignancies

Interventions

  • Parsaclisib
  • parsaclisib + itacitinib
  • parsaclisib + ruxolitinib
  • parsaclisib + ibrutinib

Phase

Phase 2

Study Type

Interventional

Further Study Details

Primary Outcome:

  • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Enrollment

31

Study Start Date

August 3, 2020

Eligibility

  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No

Sponsors

Incyte Corporation

Source

Incyte Corporation

Official title

A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Clinicaltrials.gov Identifier

NCT04509700

     

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.